<DOC>
	<DOCNO>NCT02061332</DOCNO>
	<brief_summary>Women diagnose Her-2/neu over-expressing DCIS receive DC1 vaccine intranodal , intralesional , rout administration . The primary objective safety administration secondary objective immune activation clinical response .</brief_summary>
	<brief_title>DC Vaccine Patients With Ductal Carcinoma In Situ</brief_title>
	<detailed_description>The treatment patient DCIS individualize tailor type DCIS relative risk lesion . HER-2/neu over-expressing DCIS represent group patient significant risk development invasive breast cancer . In proposal continue evaluate development type I polarize DC treatment DCIS evaluate whether improvement therapeutic response achieve intratumoral administration HER-2/neu pulse DC1 compare current intranodal administration . Women diagnose Her-2/neu over-expressing DCIS invasive carcinoma eligible study . Patients receive DC1 vaccine intranodal , intralesional , rout administration . The primary objective safety administration secondary objective immune activation clinical response . We also develop novel assay monitor ongoing immunity HER-2/neu , lastly begin develop vaccine patient invasive breast cancer well . Fifty-four subject randomize one three treatment arm : intranodal injection , intralesional injection , intranodal intralesional injection vaccine . Upon enter study , subject ' blood drawn way collect white blood cell . Subjects receive six vaccine six week period . They undergo standard surgical procedure remove remain DCIS breast .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age &gt; 18 year . Subjects biopsyproven DCIS , DCIS microinvasion , DCIS invasive disease 5 mm , Paget 's Disease nipple ( DCIS nipple ) yet receive definitive treatment . HER2/neu positive tumor determine &gt; 5 % tumor population express marker immunohistochemical stain 2+ use antiHER2/neu verify Dr. Paul Zhang Department Pathology . Women childbearing age negative pregnancy test document prior enrollment . Subjects ECOG Performance Status Score 0 1 ( Appendix D ) . Subjects willing use birth control necessary Subjects voluntarily sign write Informed Consent accordance institutional policy content fully explain . Pregnant lactating female ( pregnancy test perform within 7 day prior administration first dose vaccine ) . Subjects complete excisional biopsy tumor . Subjects suspicion invasive disease &gt; 5mm MRI perform within 2 month study recruitment . Screen exclude subject positive HIV hepatitis C baseline . Subjects coagulopathies , include thrombocytopenia platelet count &lt; 75,000 , INR &gt; 1.5 partial thromboplastin time &gt; 50 sec Subjects major cardiac illness MUGA &lt; 50 % EF . Subjects preexist medical illness medication might interfere study . Subjects laboratory test reflect Â¬ &gt; grade 1 toxicity NCI CTC version 3.0 include CBC , liver function test , urinalysis , EKG correct repeat test 7 day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>DCIS</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Dendritic Cell</keyword>
</DOC>